Researchers at the Texas A&M Health Science Center (HSC) Institute of Biosciences and Technology at Houston have discovered a gene’s unique role in atrial fibrillation, a finding that could eventually help in developing treatments for a disease affecting millions of Americans.
Researchers at the TAMHSC Institute of Biosciences and Technology in Houston have uncovered a potential mechanism that could prevent cancer at its origin.
The Texas A&M Institute for Genomic Medicine (TIGM) – a research institute of the Texas A&M Health Science Center – has created a grant-in-aid program specifically to assist University of Texas Medical Branch at Galveston (UTMB) scientists obtain access to research materials in an effort to help speed the recovery of UTMB’s research programs from some of the injuries caused by Hurricane Ike.
China and Taiwan have been at odds for years, but the TAMHSC Institute of Biosciences and Technology is working to bridge the “Taiwan Strait” by helping develop a new cancer center in China.
The Texas A&M Institute for Genomic Medicine (TIGM) – a joint research institute of the TAMHSC and Texas A&M University – is a co-recipient of a $3.2 million grant from the Environmental Protection Agency and its Science to Achieve Results (STAR) program. The primary objective of the grant is to study current human health risk from chemical exposures.
HSC spin-off company NanoRelease Technologies receives Recovery Act supplement funds for vaccine development training
The Texas A&M Health Science Center (HSC) Center for Microencapsulation and Drug Delivery (CMDD) is hosting three students and a science educator who are trainees supported with National Institutes of Health American Recovery and Reinvestment Act funds for vaccine development training.
Researchers at the Texas A&M Health Science Center (HSC) College of Medicine, in collaboration with the Vaccine Research Institute of San Diego, have created a new genetic technology to study Salmonella, a bacterium responsible for approximately 1.4 million cases of food-borne infections in the United States each year.
A Houston-based biotechnology company co-founded by a scientist at the TAMHSC Institute of Biosciences and Technology has received an investment award of $250,000 from the Texas Emerging Technology Fund (TETF).
Co-sponsored by the Texas A&M Health Science Center, the Texas A&M University chapter of Sigma Xi – the national scientific research society – will conduct a one-day symposium called “Stem Cells in Medicine” on March 25.